Neurobo Pharmaceuticals,

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Our Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and we have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, our lead Alzheimer’s drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth. An aging population has resulted in an increase in the prevalence of Alzheimer’s disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimer’s disease, yet none of these four address disease modification.